German ministers explore Futrue Neurosciences' breakthroughs in pain therapy and BCIs

Federal Health Minister Nina Warken (CDU) recently visited Futrue Neurosciences in Gräfelfing, joined by Bavaria's Health Minister Judith Gerlach and CSU parliamentary leader Klaus Holetschek. The trip followed a similar visit by Bavarian Minister-President Markus Söder (CSU) just days earlier. Discussions focused on cutting-edge medical innovations, including cannabinoid-based treatments and brain-computer interfaces (BCIs).

The delegation toured Futrue's facilities, where the company is developing two major projects. One involves Vertanical, a subsidiary working on a new class of cannabinoid-based pain therapies under the name Ver-01. Futrue also aims to introduce Exilby, a drug designed as a more effective and better-tolerated alternative to opioids. However, no clinical studies on Ver-01 have been publicly documented so far.

Another key topic was Futrue Neurosciences' work on brain-computer interfaces (BCIs). These devices could potentially restore lost bodily functions and create new ways for humans to interact with machines. The talks emphasised Germany's ambition to become a leading innovation hub, with calls for greater investment, flexible regulations, and forward-looking policies. All parties agreed on the need for a strategic approach to support medical and technological advancements in the country.

The visit highlighted Futrue's role in advancing both pain management and neurotechnology. With ongoing projects like Exilby and BCIs, the company is positioning itself at the forefront of medical innovation. Meanwhile, political leaders stressed the importance of fostering an environment that accelerates research and development in these fields.